China Resources Sanjiu Medical & Pharma (000999) Earnings Surge: 1H Net Income Soars 28% to 2.40B Yuan

China Resources Sanjiu Medical & Pharma on Smartkarma

On Smartkarma, a platform for independent investment research, analyst Xinyao (Criss) Wang provides insights on China Resources Sanjiu Medical & Pharma. In a bullish analysis titled “CR Sanjiu (000999.CH) To Acquire Tasly Pharma (600535.CH) – SOEs Have High Enthusiasm for TCM Assets,” Wang discusses China Resources Sanjiu’s acquisition of a 28% stake in Tasly for RMB6.21 billion. Aligned with the strategic goals of the 14th Five-Year Plan, the acquisition is seen positively for Tasly’s valuation despite market skepticism towards China Resources Sanjiu’s decision.

Moreover, in a bearish perspective titled “China Resources Sanjiu (000999.CH) – 2023 Results Below Expectations; Short-Term Headwinds Remain,” Wang highlights Sanjiu’s disappointing 2023 results and anticipates lower growth in 2024. The performance dip is attributed to various factors such as TCM formula granules pricing and anti-corruption measures. Despite challenges, Sanjiu aims for revenue growth in 2024 through its prescription drug business, particularly the TCM injection segment, buoyed by favorable medical insurance policies. Wang expects performance growth in 2024 to lag behind that of 2023.

A look at China Resources Sanjiu Medical & Pharma Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is positioned well for long-term success, according to Smartkarma’s Smart Scores. With a Growth score of 5, the company is expected to expand significantly over time, indicating strong potential for future growth and development. Additionally, its Momentum score of 5 suggests that the company is currently on a positive trajectory, likely to continue performing well in the coming years.

Furthermore, the company’s Dividend and Resilience scores of 4 each indicate stability and reliability in terms of dividend payments and overall resilience to market fluctuations. While the Value score of 2 implies that the stock may be slightly overvalued, the strong scores in other areas paint a positive picture of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.’s long-term outlook in the medical and pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma